Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
April 17, 2024 01:15 ET
|
Novartis Pharma AG
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis...
Artificial Intelligence / AI in Drug Discovery Research Report 2023 - Global Forecast to 2028: Market to Grow by $4 Billion, at a CAGR of 40.2%
February 27, 2024 03:18 ET
|
Research and Markets
Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Artificial Intelligence / AI in Drug Discovery Market by Offering, Process (Target selection, Validation, Lead Generation, Optimization), Drug Design...
Emerging Drug Insight and Market Forecasts for YG1699 in Type 1 Diabetes Mellitus, 2019-2023 and 2023-2032
January 24, 2024 09:12 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "YG1699 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. Understanding the future market...
Peter Madrid, Head of Scientific Discovery at Synfini, Joins Other Expert Speakers to Lead a National Academies of Sciences Workshop on AI for Scientific Discovery
October 11, 2023 14:29 ET
|
Synfini
MENLO PARK, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Synfini, Inc., a pioneer in agile chemistry whose advanced, automated molecular discovery platform is transforming drug discovery, today...
Global CADD Market Expected to Reach $7.81 Billion by 2030, Driven by Growing Demand for Advanced Drug Discovery
September 29, 2023 05:03 ET
|
Research and Markets
Dublin, Sept. 29, 2023 (GLOBE NEWSWIRE) -- The "Computer-aided Drug Discovery Market: Global Market Size, Forecast, Insights, and Competitive Landscape" report has been added to ...
Technology-enabled Drug Discovery Research Report 2023: AI Integration into Drug Discovery Remains on an Upward Trajectory, Increasing Almost 40% as of 2022
August 08, 2023 04:43 ET
|
Research and Markets
Dublin, Aug. 08, 2023 (GLOBE NEWSWIRE) -- The "Growth Indicators for Technology-enabled Drug Discovery" report has been added to ResearchAndMarkets.com's offering. Innovative Business Models...
Insilico Medicine Founder and CEO to Give Keynote on Disease Modeling with AI at PEGS Boston
May 12, 2023 16:39 ET
|
InSilico Medicine
Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced that Alex Zhavoronkov, PhD, founder and CEO of the...
Outlook on the Deep Learning Drug Discovery and Diagnostics Global Market to 2035: by Therapeutic Areas and Key Geographical Regions
March 16, 2023 05:53 ET
|
Research and Markets
Dublin, March 16, 2023 (GLOBE NEWSWIRE) -- The "Deep Learning Market in Drug Discovery and Diagnostics: Distribution by Therapeutic Areas and Key Geographical Regions: Industry Trends and Global...
Global In-Silico Drug Discovery Market Report 2022: Industry Outlook and Demand Forecast to 2030 Featuring In-silico Medicine, Evotec, Charles River Labs, WuXi AppTec, Ligand Pharma, Simulation Plus
March 01, 2023 10:28 ET
|
Research and Markets
Dublin, March 01, 2023 (GLOBE NEWSWIRE) -- The "Global In-Silico Drug Discovery Market Report: By Product, Workflow, Technology, End-user - Industry Outlook and Demand Forecast to 2030" report has...
Insilico Medicine Receives FDA Orphan Drug Designation for Generative AI Discovered and Designed Drug for Idiopathic Pulmonary Fibrosis
February 08, 2023 09:00 ET
|
InSilico Medicine
New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, today announced that...